Clinical trials
Phase 1/2 Basal Cell Carcinoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 3 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Recruiting | 4 |
| Active, not recruiting | 2 |
| Terminated | 2 |
| Suspended | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Merete Haedersdal | 2 |
| AiViva BioPharma, Inc. | 1 |
| Anne Chang | 1 |
| Ascend Biopharmaceuticals Ltd | 1 |
| Bruce Robinson, MD | 1 |
| Ivan Litvinov | 1 |
| Joint Authority for Päijät-Häme Social and Health Care | 1 |
| Marengo Therapeutics, Inc. | 1 |
| Medicenna Therapeutics, Inc. | 1 |
| National Cancer Institute (NCI) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Basal Cell Carcinoma | 17 |
| Skin Neoplasms | 6 |
| Carcinoma, Merkel Cell | 4 |
| Melanoma | 4 |
| Carcinoma, Squamous Cell | 3 |
| Neoplasms | 3 |
| Carcinoma | 2 |
| Colorectal Neoplasms | 2 |
| Endometrial Neoplasms | 2 |
| Esophageal Neoplasms | 2 |
Trials
Showing 51 to 17 of 17. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.